Selected research
Industry Research
Potassium Channel Blocker Industry Research Report 2026
Market perspective
The global Potassium Channel Blocker market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Potassium Channel Blocker is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Potassium Channel Blocker is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Potassium Channel Blocker is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Potassium Channel Blocker include Novartis, GlaxoSmithKline, Amgen, Sevion Therapeutics, Regeneron, North Coast Bio, KPI Therapeutics, Kineta and F-star, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Potassium Channel Blocker market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Potassium Channel Blocker Market by Company
Novartis
GlaxoSmithKline
Amgen
Sevion Therapeutics
Regeneron
North Coast Bio
KPI Therapeutics
Kineta
F-star
Enumeral
Cono Genetix
Bristol-Myers Squibb
Agenus bio
Potassium Channel Blocker Segment by Type
Clinical
Non-clinical
Potassium Channel Blocker Segment by Application
Clinic
Hospital
Potassium Channel Blocker Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Potassium Channel Blocker market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Potassium Channel Blocker and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Potassium Channel Blocker.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Potassium Channel Blocker manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Potassium Channel Blocker by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Potassium Channel Blocker in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Clinical
- Non-clinical
Applications
- Clinic
- Hospital
Companies covered
- Novartis
- GlaxoSmithKline
- Amgen
- Sevion Therapeutics
- Regeneron
- North Coast Bio
- KPI Therapeutics
- Kineta
- F-star
- Enumeral
- Cono Genetix
- Bristol-Myers Squibb
- Agenus bio
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Potassium Channel Blocker Market Size (2021-2032)
- 2.2.2 Global Potassium Channel Blocker Sales (2021-2032)
- 2.2.3 Global Potassium Channel Blocker Market Average Price (2021-2032)
- 2.3 Potassium Channel Blocker by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Clinical
- 2.3.3 Non-clinical
- 2.4 Potassium Channel Blocker by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Potassium Channel Blocker Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Potassium Channel Blocker Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Potassium Channel Blocker Revenue of Manufacturers (2021-2026)
- 3.4 Global Potassium Channel Blocker Average Price by Manufacturers (2021-2026)
- 3.5 Global Potassium Channel Blocker Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Potassium Channel Blocker, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Potassium Channel Blocker, Product Type & Application
- 3.8 Global Manufacturers of Potassium Channel Blocker, Established Date
- 3.9 Global Potassium Channel Blocker Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis Potassium Channel Blocker Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 GlaxoSmithKline
- 4.2.1 GlaxoSmithKline Company Information
- 4.2.2 GlaxoSmithKline Business Overview
- 4.2.3 GlaxoSmithKline Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Potassium Channel Blocker Product Portfolio
- 4.2.5 GlaxoSmithKline Recent Developments
- 4.3 Amgen
- 4.3.1 Amgen Company Information
- 4.3.2 Amgen Business Overview
- 4.3.3 Amgen Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Amgen Potassium Channel Blocker Product Portfolio
- 4.3.5 Amgen Recent Developments
- 4.4 Sevion Therapeutics
- 4.4.1 Sevion Therapeutics Company Information
- 4.4.2 Sevion Therapeutics Business Overview
- 4.4.3 Sevion Therapeutics Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sevion Therapeutics Potassium Channel Blocker Product Portfolio
- 4.4.5 Sevion Therapeutics Recent Developments
- 4.5 Regeneron
- 4.5.1 Regeneron Company Information
- 4.5.2 Regeneron Business Overview
- 4.5.3 Regeneron Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Regeneron Potassium Channel Blocker Product Portfolio
- 4.5.5 Regeneron Recent Developments
- 4.6 North Coast Bio
- 4.6.1 North Coast Bio Company Information
- 4.6.2 North Coast Bio Business Overview
- 4.6.3 North Coast Bio Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 North Coast Bio Potassium Channel Blocker Product Portfolio
- 4.6.5 North Coast Bio Recent Developments
- 4.7 KPI Therapeutics
- 4.7.1 KPI Therapeutics Company Information
- 4.7.2 KPI Therapeutics Business Overview
- 4.7.3 KPI Therapeutics Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 KPI Therapeutics Potassium Channel Blocker Product Portfolio
- 4.7.5 KPI Therapeutics Recent Developments
- 4.8 Kineta
- 4.8.1 Kineta Company Information
- 4.8.2 Kineta Business Overview
- 4.8.3 Kineta Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Kineta Potassium Channel Blocker Product Portfolio
- 4.8.5 Kineta Recent Developments
- 4.9 F-star
- 4.9.1 F-star Company Information
- 4.9.2 F-star Business Overview
- 4.9.3 F-star Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 F-star Potassium Channel Blocker Product Portfolio
- 4.9.5 F-star Recent Developments
- 4.10 Enumeral
- 4.10.1 Enumeral Company Information
- 4.10.2 Enumeral Business Overview
- 4.10.3 Enumeral Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Enumeral Potassium Channel Blocker Product Portfolio
- 4.10.5 Enumeral Recent Developments
- 4.11 Cono Genetix
- 4.11.1 Cono Genetix Company Information
- 4.11.2 Cono Genetix Business Overview
- 4.11.3 Cono Genetix Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Cono Genetix Potassium Channel Blocker Product Portfolio
- 4.11.5 Cono Genetix Recent Developments
- 4.12 Bristol-Myers Squibb
- 4.12.1 Bristol-Myers Squibb Company Information
- 4.12.2 Bristol-Myers Squibb Business Overview
- 4.12.3 Bristol-Myers Squibb Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Bristol-Myers Squibb Potassium Channel Blocker Product Portfolio
- 4.12.5 Bristol-Myers Squibb Recent Developments
- 4.13 Agenus bio
- 4.13.1 Agenus bio Company Information
- 4.13.2 Agenus bio Business Overview
- 4.13.3 Agenus bio Potassium Channel Blocker Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Agenus bio Potassium Channel Blocker Product Portfolio
- 4.13.5 Agenus bio Recent Developments
5 Global Potassium Channel Blocker Market Scenario by Region
- 5.1 Global Potassium Channel Blocker Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Potassium Channel Blocker Sales by Region: 2021-2032
- 5.2.1 Global Potassium Channel Blocker Sales by Region: 2021-2026
- 5.2.2 Global Potassium Channel Blocker Sales by Region: 2027-2032
- 5.3 Global Potassium Channel Blocker Revenue by Region: 2021-2032
- 5.3.1 Global Potassium Channel Blocker Revenue by Region: 2021-2026
- 5.3.2 Global Potassium Channel Blocker Revenue by Region: 2027-2032
- 5.4 North America Potassium Channel Blocker Market Facts & Figures by Country
- 5.4.1 North America Potassium Channel Blocker Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Potassium Channel Blocker Sales by Country (2021-2032)
- 5.4.3 North America Potassium Channel Blocker Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Potassium Channel Blocker Market Facts & Figures by Country
- 5.5.1 Europe Potassium Channel Blocker Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Potassium Channel Blocker Sales by Country (2021-2032)
- 5.5.3 Europe Potassium Channel Blocker Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Potassium Channel Blocker Market Facts & Figures by Country
- 5.6.1 Asia Pacific Potassium Channel Blocker Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Potassium Channel Blocker Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Potassium Channel Blocker Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Potassium Channel Blocker Market Facts & Figures by Country
- 5.7.1 South America Potassium Channel Blocker Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Potassium Channel Blocker Sales by Country (2021-2032)
- 5.7.3 South America Potassium Channel Blocker Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Potassium Channel Blocker Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Potassium Channel Blocker Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Potassium Channel Blocker Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Potassium Channel Blocker Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Potassium Channel Blocker Sales by Type (2021-2032)
- 6.1.1 Global Potassium Channel Blocker Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Potassium Channel Blocker Sales Market Share by Type (2021-2032)
- 6.2 Global Potassium Channel Blocker Revenue by Type (2021-2032)
- 6.2.1 Global Potassium Channel Blocker Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Potassium Channel Blocker Revenue Market Share by Type (2021-2032)
- 6.3 Global Potassium Channel Blocker Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Potassium Channel Blocker Sales by Application (2021-2032)
- 7.1.1 Global Potassium Channel Blocker Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Potassium Channel Blocker Sales Market Share by Application (2021-2032)
- 7.2 Global Potassium Channel Blocker Revenue by Application (2021-2032)
- 7.2.1 Global Potassium Channel Blocker Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Potassium Channel Blocker Revenue Market Share by Application (2021-2032)
- 7.3 Global Potassium Channel Blocker Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Potassium Channel Blocker Value Chain Analysis
- 8.1.1 Potassium Channel Blocker Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Potassium Channel Blocker Production Mode & Process
- 8.2 Potassium Channel Blocker Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Potassium Channel Blocker Distributors
- 8.2.3 Potassium Channel Blocker Customers
9 Global Potassium Channel Blocker Analyzing Market Dynamics
- 9.1 Potassium Channel Blocker Industry Trends
- 9.2 Potassium Channel Blocker Industry Drivers
- 9.3 Potassium Channel Blocker Industry Opportunities and Challenges
- 9.4 Potassium Channel Blocker Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst